Oncology:
Our other therapy areas

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • This website is for UK Healthcare Professionals only

      *Remission is based on CR, ORR and PR. CR is defined in the SmPC as complete remission.
      UK-VNCCLL-220184 | May 2022

      UK-VNCCLL-230003. Date of Preparation: March 2023.

      VENCLYXTO®▼ (venetoclax) combinations are
      NICE recommended as an option across
      all licensed indications1,4,5

       

      Which of your patients could benefit from VENCLYXTO combinations?

      triangle
      triangle

      Venetoclax in combination with rituximab, is recommended, within its marketing authorisation, as an option for treating chronic lymphocytic leukaemia in adults who have had at least 1 previous therapy. It is recommended only if the company provides it according to the commercial agreement.

      Venetoclax plus obinutuzumab is recommended as an option for untreated chronic lymphocytic leukaemia (CLL) in adults, only if:

      • there is a 17p deletion or TP53 mutation, or
      • there is no 17p deletion or TP53 mutation, and fludarabine plus cyclophosphamide and rituximab (FCR), or bendamustine plus rituximab (BR), is unsuitable, and
      • the company provides the drug according to the commercial arrangement.

      Venetoclax plus obinutuzumab is recommended for use within the Cancer Drugs Fund as an option for untreated CLL in adults, only if:

      • there is no 17p deletion or TP53 mutation, and FCR or BR is suitable, and
      • the conditions in the managed access agreement for venetoclax plus obinutuzumab are followed.

      Discover next…

      VENCLYXTO clinical data
      VENCLYXTO resources
      Contact us

      CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; SmPC=Summary of product characteristics.

      References

      1. VENCLYXTO Summary of Product Characteristics. 
      2. Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20. 
      3. Fischer K et al. N Engl J Med. 2019; 380: 2225–36.
      4. NICE TAG TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia https://www.nice.org.uk/guidance/ta561 (accessed May 2022). 
      5. NICE TAG TA663: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia https://www.nice.org.uk/guidance/ta663 (accessed May 2022). 

       

      VENCLYXTO PRESCRIBING INFORMATION

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected]

      UK-VNCCLL-220195. Date of preparation: May 2022.